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The vasculitides are a heterogeneous group of diseases, comprising necrotizing and nonnecrotizing 
vessel diseases. Patients with vasculitis frequently develop infections, mainly as a consequence of 
treatments prescribed to treat their disease. Corticosteroids, immunosuppressants, and most 
immunomodulating agents (eg, anti–tumor necrosis factor or anti-CD20 monoclonal antibodies) facilitate 
infections, and combined therapies further increase that risk.
1
 In immunosuppressed patients, infections 
are sometimes life threatening and are one of the major causes of deaths.
1 
 
However, active vasculitis and infection can coexist, and treatment for these conditions is a challenge for 
physicians. Therefore, alternative therapeutic approaches rather than conventional 
immunosuppressants are needed to limit the disease activity when a concomitant infection is suspected. 
 
Intravenous immunoglobulin (IVIG) has been used as a replacement therapy in patients with primary and 
secondary immunodeficiencies and in the treatment of many autoimmune and systemic inflammatory 
disorders.
2
 Moreover, their potential role against infections has been speculated.
3
 In the spectrum of 
systemic vasculitis, there is clear evidence of the benefit of IVIG in Kawasaki disease, and it is now also 
considered a therapeutic option in refractory antineutrophil cytoplasmic antibody–associated vasculitis.
4
, 
5
 
For other vasculitis, such as polyarteritis nodosa, Henoch-Schönlein purpura (HSP), or Behçet disease (BD), 
only a few case reports have described a beneficial effect of IVIG. 
 
We report the largest cohort focusing on clinical effects of IVIG in patients with active vasculitis 
and concomitant infection. 
 
METHODS 
 
This observational, retrospective study included 14 patients with vasculitis and concomitant infection 
attending the Louise Coote Lupus Unit at St Thomas Hospital, London, or the Centro di Ricerche di 
Immunologia Clinica ed Immunopatologia e Documentazione su Malattie Rare, Università di Torino, Italy, 
from January 2001 to February 2012, who received at least 1 cycle of IVIG (400 mg/kg per day for 5 days). 
 
The underlying vasculitic disorder was granulomatosis with polyangiitis (GPA) in 5 patients, 2 patients with 
Churg-Strauss syndrome, 2 patients with cutaneous vasculitis, and microscopic polyangiitis (MPA), HSP, 
BD, pulmonary and systemic small-sized vasculitis were diagnosed in 1 patient, respectively. All the 
patients fulfilled the current classification criteria 
6
 for the diagnosed vasculitis. All patients received high-
dose IVIG (0.4 g/kg per day) during 5 days on the grounds of a suspected or proven concomitant infection. 
 
Intravenous immunoglobulin was added after immunosuppression had been discontinued. Patients were 
evaluated by a rheumatologist as an inpatient and during follow-up. The resolution of the acute episode of 
infection and concomitant active vasculitis causing the referral to our units constituted the endpoint. The 
outcome was classified as no response, partial remission, or complete remission according to the global 
physician assessment, improvement in disease activity according to clinical and analytical parameters. 
 
The diagnosis of infection was based on the positive culture results of a pathogenic microorganism. For those 
with negative results of microorganism culture, infection was diagnosed by typical symptoms, signs, imaging 
investigations, and laboratory evaluations, combined with positive response to the standard 
 
antibacterial therapy. In patients who achieved complete or partial remission, immunosuppressant therapy 
was reintroduced or added after infection subsided. 
 
RESULTS 
 
The results are summarized in the Table 1. All but 1 patient (patient 5) had received immunosuppression 
and/or intravenous (IV) corticosteroids prior to treatment with IVIG. Patient 5 was admitted with a first 
presentation of MPA and concomitantly developed hospital-acquired pneumonia. 
 
Seven patients (50%) achieved complete remission (3 GPA, 2 Churg-Strauss syndrome, 1 
pulmonary vasculitis, and 1 cutaneous vasculitis); 3 (21%) achieved partial remission (1 HSP, 1 
MPA, 1 systemic vasculitis); and 4 (29%) did not respond (2 GPA, 1 BD, 1 cutaneous vasculitis). 
 
Among the patients with complete or partial response (71%), the time free of relapse during the 24-
month follow-up was 20.9 ± 8.5 months. 
 
Three patients died: patient 7 with acute interstitial pneumonia and patients 6 and 10 with sepsis. No 
adverse effects of IVIG were reported. An infectious agent was identified in all patients (Table 1) except in 
patient 11, admitted because of severe hemoptysis, shortness of breath, and fever. His blood test 
showed elevated markers of inflammation and leukocytosis. A computed tomography scan of the chest 
reported multifocal consolidations. 
 
All the patients were treated with concomitant antibiotic therapy based on the results of 
microorganism culture. 
 
DISCUSSION 
 
Intravenous immunoglobulin has long been used as a rescue medication in autoimmune conditions.
7–
 
9
However, available data on the use of IVIG in vasculitis and concomitant infection rely mainly on a 
large number of case reports. Vasculitis can be life threatening, and infections are one of the major 
causes of death. It has been reported in a prospective study, among the observed 85 of 278 fatalities, 
11 patients (12.4%) died of infections (5 of bacterial pneumonia and 6 with septicemia).
10
 In another 
study on the causes of early vasculitis-associated deaths, 13 of 60 fatalities during the first year after 
diagnosis were attributed to infections.
11 
 
This observational, retrospective, chart- and database-driven, 2-center clinical study aimed to evaluate the 
beneficial effects and safety profile of high-dose IVIG in the largest series of vasculitis patients with 
concomitant infections. The clinical features presented in our cohort at the time of IVIG administration 
included cutaneous, hematological, and lower and upper respiratory tract. Our study emphasizes that 
treatment with IVIG is effective, with more than 70% of the patients experiencing any benefit, with total 
or partial remission. 
 
Recently, in a meta-analysis about the use of IVIG in GPA, it has been proposed that the mechanisms 
of action of IVIG may involve both anti-inflammatory and antimicrobial properties.
7–9, 12–15
 Based on 
this assumption, we have hypothesized that IVIG may be beneficial in patients with a flare of a primary 
vasculitis and concomitant severe infection, particularly useful when the temporary discontinuation of 
immunosuppressive therapy is required. 
 
However, IVIG was not used specifically to treat infections or sepsis, as it has not been proven to be 
effective for these indications,
16, 17
 but it was considered the safest option to treat vasculitis activity 
because immunosuppressive therapies could lead to a worsening of the infection. In these patients, the 
 
beneficial effects of IVIG are most probably multifactorial, acting through complement deactivation, 
receptor blockade, anti-idiotypes, and modulation of cytokine production. Treatment with IVIG was aimed 
to treat the activity of the disease without producing severe immunosuppression, whereas the 
concomitant antibiotic therapy would aim to improve the infection. Our experience is consistent with the 
reported major advantage of the use of IVIG in vasculitis, as it seems also to prevent infections due to the 
B-cell deficit induced by combined steroids and cytotoxic agents.
1 
 
In this study, IVIGs were administered at the dose of 0.4 g/kg per day during 5 days based on our previous 
experience in autoimmune diseases other than vasculitides.
18
 We acknowledge that other schemes (2 
g/kg administered over either 2 or 5 consecutive days) have been used to treat rheumatic diseases.
9
 The 
difference between these 2 regimens has not been fully investigated. 
 
We acknowledge that the interpretation of our results has to be taken with caution because the series 
is heterogeneous regarding the type of vasculitis and infections. 
 
Nevertheless, the favorable outcome of 10 patients is encouraging, particularly because in our series 
IVIG was added only when the clinical condition of the patient had deteriorated, and it was sensed that 
antibiotic treatment might not be sufficient. Three patients died despite IVIG, as anecdotally reported in 
the literature, especially when active disease is associated with viral infection.
19 
 
In conclusion, in this cohort, IVIG was found to be effective in selected cases of vasculitis, when other 
therapeutic approaches (mainly immunosuppressors) were not appropriate, such as in patients with 
active disease and concomitant infection. Considering costs and limited availability of IVIGs treatment, we 
would recommend that randomized controlled trials are needed to support these observations. 
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TABLE 1 Demographic and Clinical Characteristics of the Patients Treated With IVIG 
 
 
Mechanism Agent 
Targeting surface molecules on B cells Ocrelizumab (fully humanized anti-CD20) 
Epratuzumab (fully humanized anti-CD22) 
Targeting B cell growth and survival factors Atacicept 
Blisibimod 
Tabalumab 
Toleragen molecule Abetimus sodium 
Proteasome inhibition Bortezomib 
Targeting co-stimulatory molecules AMG 557 (against B7RP-1, an inducible co-stimulator ligand) 
Targeting T cells Edratide 
Rigerimod 
Laquinimod 
Targeting cytokines — IL 6 Tocilizumab 
Sirukumab 
Targeting cytokines — type I interferons Sifalimumab 
Rontalizumab 
 
